A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Francis J Giles, MD
Institute for Drug Development (IDD), Cancer Therapy and Research Center, San Antonio, Texas, USA
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hematology Service, Hôpital Beaujon and Hôpital Avicenne
Bobigny, Paris, France
- Centre Hospitalier Universitaire, Chu de Lyon, Service D'Hematologie Clinique
Lyon, France
- Institut Paoli-Calmettes
Marseille, France
- Centre Hospitalier Universitaire Chu de Toulouse, Hopital Purpan
Toulouse, France
- University Hospital Benjamin Franklin Med.Clinic Iii
Berlin, Germany
- Department of Internal Medicine Klinikum Der Johann Wolfgang Goethe-Universität Medizinische Klinik Ii
Frankfurt am Main, Germany
- Westfälische Wilhelms-Universität Münster Medizinische Klinik Und Polikinik Innere Medizin A
Münster, Germany
- Institute of Hematology & Medical Oncology L and A Serágnoli University of Bologna
Bologna, Italy
- Universitá Degli Studi Di Roma Ematologia- Policlinico Tor Vergata
Rome, Italy
- Department of Hematology, Ullevål University Hospital, University of Oslo
Oslo, Norway
- Christie Hospital
Manchester, United Kingdom
- Mew York Medical College, Division of Oncology
Valhalla, New York, United States
- Duke University Medical Center (dumc)
Durham, North Carolina, United States
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Institute for Drug Development (idd), Cancer Therapy and Research Center, 7979 Wurzbach Rd.
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2006
- Primary completion
- 31 May 2009
- Completion
- 31 May 2010
- Last update posted
- 18 Sept 2013
- Registered enrollment
- 153
- Registry id
- NCT00405743
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.